Post-Pandemic Aftermath: A Two-Year Follow-Up of the Effect of COVID-19 on Oncological Outcomes after Radical Prostatectomy for Prostate Cancer.
COVID
lockdown
oncological outcomes
prostatectomy
Journal
Archivos espanoles de urologia
ISSN: 0004-0614
Titre abrégé: Arch Esp Urol
Pays: Spain
ID NLM: 0064757
Informations de publication
Date de publication:
Jan 2024
Jan 2024
Historique:
medline:
20
2
2024
pubmed:
20
2
2024
entrez:
19
2
2024
Statut:
ppublish
Résumé
This study aimed to evaluate the indirect effect of the Coronavirus Disease 2019 (COVID-19) pandemic on the surgical outcomes and oncological results of patients who underwent surgery during the lockdown period. We analysed data from 423 patients who underwent radical prostatectomy between 2016 and 2022, with a cut-off date of March 16, 2020. Patients were categorised into two groups, namely, pre-lockdown (n = 289) and during lockdown (n = 134). Perioperative variables, histopathological findings and oncological outcomes, including prostate-specific antigen (PSA) levels and biochemical recurrence (BCR), were assessed. The number of radical prostatectomy increased by 24.26% during lockdown. The study included patients with a mean follow-up of 21 months. A nonsignificant trend towards a higher PSA level at presentation was found (14.22 vs. 12.53 ng/dL, The COVID-19 pandemic led to poor postoperative results. Through a 2-year follow-up, this research investigated the effect of the pandemic on the oncological outcomes, particularly BCR, of patients who underwent radical prostatectomy. Further extended investigations and multi-institutional studies should be conducted to quantify the effect of the pandemic on various cancer outcomes and inform crisis management strategies.
Identifiants
pubmed: 38374012
pii: 1706774234799-204394203
doi: 10.56434/j.arch.esp.urol.20247701.6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
43-48Informations de copyright
© 2024 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.